These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6606021)

  • 1. Role of T-lymphocyte subsets in tumor rejection: implications for developing biological response modifiers and monitoring tumor--host interactions during tumor development.
    Robins RA; Baldwin RW
    J Biol Response Mod; 1983; 2(2):101-9. PubMed ID: 6606021
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immunology.
    Klein G
    Transplant Proc; 1973 Mar; 5(1):31-41. PubMed ID: 4348706
    [No Abstract]   [Full Text] [Related]  

  • 4. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
    Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET
    J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
    Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
    Yoneda Y; Yoshida R
    J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.
    Monach PA; Schreiber H; Rowley DA
    Transplantation; 1993 Jun; 55(6):1356-61. PubMed ID: 8100090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression patterns of CD44 and CD45RB on peripheral blood T lymphocytes in the rejection of allogeneic murine skin transplantation.
    Yang J; Ahn C; Jung HK; Kim EK; Kim JY; Kim YS; Han JS; Kim S; Lee JS
    Transpl Immunol; 2003; 11(2):197-206. PubMed ID: 12799204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host alloresponses to treat nonlymphohematopoietic tumors: is there a solid approach?
    Sykes M
    J Immunother; 2001; 24(2):101-3. PubMed ID: 11265765
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses.
    Uekusa Y; Gao P; Yamaguchi N; Tomura M; Mukai T; Nakajima C; Iwasaki M; Takeuchi N; Tsujimura T; Nakazawa M; Fujiwara H; Hamaoka T
    J Leukoc Biol; 2002 Nov; 72(5):864-73. PubMed ID: 12429708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
    Apasov SG; Sitkovsky MV
    J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.
    Kelly JM; Darcy PK; Markby JL; Godfrey DI; Takeda K; Yagita H; Smyth MJ
    Nat Immunol; 2002 Jan; 3(1):83-90. PubMed ID: 11743585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
    Nguyen VH; Zeiser R; Negrin RS
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):995-1009. PubMed ID: 17084366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762.
    Frey AB
    J Immunol; 1996 May; 156(10):3841-9. PubMed ID: 8621922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.